Featured Research

from universities, journals, and other organizations

Few women at high-risk for hereditary breast, ovarian cancer receive genetic counseling

Date:
May 8, 2014
Source:
Virginia Commonwealth University
Summary:
Mutations in the BRCA1 and BRCA2 genes account for nearly 25 percent of hereditary breast cancers and most hereditary ovarian cancers, yet a study by cancer prevention and control researchers suggests an alarmingly small amount of women who qualify for BRCA genetic counseling actually receive the services. Additionally, they found that a significant proportion of women with a family history of breast and ovarian cancer underestimate their risk.

Mutations in the BRCA1 and BRCA2 genes account for nearly 25 percent of hereditary breast cancers and most hereditary ovarian cancers, yet a study by cancer prevention and control researchers at Virginia Commonwealth University Massey Cancer Center suggests an alarmingly small amount of women who qualify for BRCA genetic counseling actually receive the services. Additionally, they found that a significant proportion of women with a family history of breast and ovarian cancer underestimate their own risk.

The study, published in the April edition of the Journal of Community Genetics, collected data from 486 women over the course of two years. Of these women, 22 met the criteria to be referred for BRCA counseling. However, only one of the women reported receiving genetic counseling and only one reported prior genetic testing. And while perceived risk of developing breast and ovarian cancer was higher among high-risk women, 27 percent of high-risk women felt their risk was "low," and 32 percent felt their risk was "lower than average." Despite having a diverse population, the researchers did not find any significant differences associated with factors such as age, race, family size or the patient's knowledge of genetic testing.

"Despite recommendations from the United States Preventive Services Task Force that primary care physicians screen for hereditary cancer risk, it seems that too few women who meet the eligibility criteria are actually following through with BRCA counseling services," says the study's lead investigator John Quillin, Ph.D., M.P.H., member of the Cancer Prevention and Control research program and genetic counselor in the Familial Cancer Clinic at Virginia Commonwealth University Massey Cancer Center and assistant professor in the Department of Human and Molecular Genetics in the VCU School of Medicine. "Unfortunately, this means that a significant number of women who are at high-risk for developing breast and ovarian cancer may not be taking advantage of preventive measures that could ultimately save their lives."

The researchers analyzed data from a pilot study called Kin Fact (Keeping Information about Family Cancer Tune-up) that was conducted at the VCU Women's Health Clinic. Kin Fact works by having a clinical research associate intervene during a woman's annual gynecology appointment to discuss the patient's genetic cancer risks. Participants were asked to complete a self-administered survey that asked questions about their knowledge of genetic counseling and their perceived cancer risk. After completing the survey, the study's recruiters obtained information about the patient's hereditary cancer risks by noting all breast and ovarian cancers among first-and second-degree relatives. The researchers' goals were to assess the amount of women eligible for BRCA counseling in a primary care setting, explore associations between high-risk status and characteristics such as age, race and genetic literacy, and determine whether high-risk patients received genetic counseling and/or testing.

"We need to examine whether patients are fully aware of their family history, and if there are ways to optimize family history collection in clinical settings," says Quillin. "This will help determine if educational interventions are needed for providers, patients or both."


Story Source:

The above story is based on materials provided by Virginia Commonwealth University. Note: Materials may be edited for content and length.


Journal Reference:

  1. John M. Quillin, Alexander H. Krist, Maria Gyure, Rosalie Corona, Vivian Rodriguez, Joseph Borzelleca, Joann N. Bodurtha. Patient-reported hereditary breast and ovarian cancer in a primary care practice. Journal of Community Genetics, 2013; 5 (2): 179 DOI: 10.1007/s12687-013-0161-1

Cite This Page:

Virginia Commonwealth University. "Few women at high-risk for hereditary breast, ovarian cancer receive genetic counseling." ScienceDaily. ScienceDaily, 8 May 2014. <www.sciencedaily.com/releases/2014/05/140508141833.htm>.
Virginia Commonwealth University. (2014, May 8). Few women at high-risk for hereditary breast, ovarian cancer receive genetic counseling. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/05/140508141833.htm
Virginia Commonwealth University. "Few women at high-risk for hereditary breast, ovarian cancer receive genetic counseling." ScienceDaily. www.sciencedaily.com/releases/2014/05/140508141833.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins